WO2014152089A1 - Compositions et traitements de troubles métaboliques à l'aide de la protéine 3 de liaison à fgf - Google Patents

Compositions et traitements de troubles métaboliques à l'aide de la protéine 3 de liaison à fgf Download PDF

Info

Publication number
WO2014152089A1
WO2014152089A1 PCT/US2014/026937 US2014026937W WO2014152089A1 WO 2014152089 A1 WO2014152089 A1 WO 2014152089A1 US 2014026937 W US2014026937 W US 2014026937W WO 2014152089 A1 WO2014152089 A1 WO 2014152089A1
Authority
WO
WIPO (PCT)
Prior art keywords
fgfbp3
amino acid
fgf19
subject
protein
Prior art date
Application number
PCT/US2014/026937
Other languages
English (en)
Inventor
Anton Wellstein
Original Assignee
Georgetown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University filed Critical Georgetown University
Publication of WO2014152089A1 publication Critical patent/WO2014152089A1/fr
Priority to US14/853,482 priority Critical patent/US9789160B2/en
Priority to US15/784,730 priority patent/US20180214514A1/en
Priority to US16/840,046 priority patent/US20200246425A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]

Abstract

L'invention concerne des méthodes de traitement d'un trouble métabolique chez un sujet, la méthode comprenant l'administration de la protéine 3 de liaison au facteur de croissance fibroblastique (FGFBP3) ou une variante de cette dernière à un sujet ayant besoin d'un traitement d'un trouble métabolique.
PCT/US2014/026937 2013-03-14 2014-03-14 Compositions et traitements de troubles métaboliques à l'aide de la protéine 3 de liaison à fgf WO2014152089A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US14/853,482 US9789160B2 (en) 2013-03-14 2015-09-14 Treatments for lowering glucose levels using FGF binding protein 3
US15/784,730 US20180214514A1 (en) 2013-03-14 2017-10-16 Compositions and Treatments of Metabolic Disorders Using FGF Binding Protein 3
US16/840,046 US20200246425A1 (en) 2013-03-14 2020-04-03 Treatments of Metabolic Disorders Using FGF Binding Protein 3

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361782382P 2013-03-14 2013-03-14
US61/782,382 2013-03-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/026938 Continuation-In-Part WO2014152090A1 (fr) 2013-03-14 2014-03-14 Compositions et traitements de troubles métaboliques employant une protéine liant fgf 3 et fgf 19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/853,482 Continuation-In-Part US9789160B2 (en) 2013-03-14 2015-09-14 Treatments for lowering glucose levels using FGF binding protein 3

Publications (1)

Publication Number Publication Date
WO2014152089A1 true WO2014152089A1 (fr) 2014-09-25

Family

ID=51581109

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/026937 WO2014152089A1 (fr) 2013-03-14 2014-03-14 Compositions et traitements de troubles métaboliques à l'aide de la protéine 3 de liaison à fgf

Country Status (1)

Country Link
WO (1) WO2014152089A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016090546A1 (fr) 2014-12-09 2016-06-16 Wentao Zhang Nbp158 et ses utilisations
WO2017083276A1 (fr) * 2015-11-09 2017-05-18 Ngm Biopharmaceuticals, Inc. Méthodes de traitement de troubles associés aux acides biliaires
US10369199B2 (en) 2013-10-28 2019-08-06 Ngm Biopharmaceuticals, Inc. Methods of using variants of FGF19 polypeptides for the treatment of cancer
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
US10413590B2 (en) 2011-07-01 2019-09-17 Ngm Biopharmaceuticals, Inc. Methods of using compositions comprising variants of FGF19 polypeptides for reducing body mass in a subject
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10456449B2 (en) 2014-06-16 2019-10-29 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US10517929B2 (en) 2014-10-23 2019-12-31 Ngm Biopharmaceuticals, Inc. Pharmaceutical compositions comprising FGF19 variants
US10758590B2 (en) 2012-11-28 2020-09-01 Ngm Biopharmaceuticals, Inc. Methods of using compositions comprising variants and fusions of FGF 19 polypeptides for treating diabetes
US11066454B2 (en) 2012-11-28 2021-07-20 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US11103554B2 (en) 2012-12-27 2021-08-31 Ngm Biopharmaceuticals, Inc. Methods of using compositions comprising variants of FGF19 polypeptides for reducing bile acid synthesis in a subject having cirrhosis
US11370841B2 (en) 2016-08-26 2022-06-28 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
US11564972B2 (en) 2012-12-27 2023-01-31 Ngm Biopharmaceuticals, Inc. Methods of using compositions comprising variants of FGF19 polypeptides for treating primary biliary cirrhosis in a subject

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090197256A1 (en) * 2002-02-28 2009-08-06 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Use of a fibroblast growth factor-binding protein for the treatment and diagnosis of diabetic wound healing problems
US20090214513A1 (en) * 2005-04-20 2009-08-27 Wyeth Mammalian expression systems
WO2010065439A1 (fr) * 2008-12-05 2010-06-10 Eli Lilly And Company Variants de facteurde croissance 21 du fibroblaste

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090197256A1 (en) * 2002-02-28 2009-08-06 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Use of a fibroblast growth factor-binding protein for the treatment and diagnosis of diabetic wound healing problems
US20090214513A1 (en) * 2005-04-20 2009-08-27 Wyeth Mammalian expression systems
WO2010065439A1 (fr) * 2008-12-05 2010-06-10 Eli Lilly And Company Variants de facteurde croissance 21 du fibroblaste

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BEENKEN, A ET AL.: "The FGF Family: Biology, Pathophysiology And Therapy.", NAT REV DRUG DISCOV., vol. 8, no. 3, March 2009 (2009-03-01), pages 235 - 253 *
YAMANAKA, Y ET AL.: "Inactivation Of Fibroblast Growth Factor Binding Protein 3 Causes Anxiety-Related Behaviors.", MOL CELL NEUROSCI., vol. 46, no. 1, January 2011 (2011-01-01), pages 200 - 212, XP027593978, DOI: doi:10.1016/j.mcn.2010.09.003 *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10413590B2 (en) 2011-07-01 2019-09-17 Ngm Biopharmaceuticals, Inc. Methods of using compositions comprising variants of FGF19 polypeptides for reducing body mass in a subject
US11065302B2 (en) 2011-07-01 2021-07-20 Ngm Biopharmaceuticals, Inc. Compositions comprising fusion variants of FGF19 polypeptides
US11066454B2 (en) 2012-11-28 2021-07-20 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US10758590B2 (en) 2012-11-28 2020-09-01 Ngm Biopharmaceuticals, Inc. Methods of using compositions comprising variants and fusions of FGF 19 polypeptides for treating diabetes
US11564972B2 (en) 2012-12-27 2023-01-31 Ngm Biopharmaceuticals, Inc. Methods of using compositions comprising variants of FGF19 polypeptides for treating primary biliary cirrhosis in a subject
US11103554B2 (en) 2012-12-27 2021-08-31 Ngm Biopharmaceuticals, Inc. Methods of using compositions comprising variants of FGF19 polypeptides for reducing bile acid synthesis in a subject having cirrhosis
US10369199B2 (en) 2013-10-28 2019-08-06 Ngm Biopharmaceuticals, Inc. Methods of using variants of FGF19 polypeptides for the treatment of cancer
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
US10456449B2 (en) 2014-06-16 2019-10-29 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US11241481B2 (en) 2014-06-16 2022-02-08 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US10517929B2 (en) 2014-10-23 2019-12-31 Ngm Biopharmaceuticals, Inc. Pharmaceutical compositions comprising FGF19 variants
US11141460B2 (en) 2014-11-07 2021-10-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US11773149B2 (en) * 2014-12-09 2023-10-03 Wentao Zhang NBP158 and uses thereof
WO2016090546A1 (fr) 2014-12-09 2016-06-16 Wentao Zhang Nbp158 et ses utilisations
CN106413739A (zh) * 2014-12-09 2017-02-15 张文涛 Nbp158及其用途
US10954282B2 (en) 2014-12-09 2021-03-23 Wentao Zhang NBP158 and uses thereof
CN106413739B (zh) * 2014-12-09 2019-09-17 张文涛 Nbp158及其用途
US20170327550A1 (en) * 2014-12-09 2017-11-16 Wentao Zhang Nbp158 and uses thereof
JP2018532749A (ja) * 2015-11-09 2018-11-08 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
JP2021185178A (ja) * 2015-11-09 2021-12-09 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
WO2017083276A1 (fr) * 2015-11-09 2017-05-18 Ngm Biopharmaceuticals, Inc. Méthodes de traitement de troubles associés aux acides biliaires
JP2020172509A (ja) * 2015-11-09 2020-10-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
US10744185B2 (en) 2015-11-09 2020-08-18 Ngm Biopharmaceuticals, Inc. Methods of using variants of FGF19 polypeptides for the treatment of pruritus
US11370841B2 (en) 2016-08-26 2022-06-28 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors

Similar Documents

Publication Publication Date Title
US20200246425A1 (en) Treatments of Metabolic Disorders Using FGF Binding Protein 3
WO2014152089A1 (fr) Compositions et traitements de troubles métaboliques à l'aide de la protéine 3 de liaison à fgf
WO2014152090A1 (fr) Compositions et traitements de troubles métaboliques employant une protéine liant fgf 3 et fgf 19
JP6621752B2 (ja) 変異した線維芽細胞増殖因子（ｆｇｆ）１および使用方法
AU2013311777B2 (en) Fusion proteins for treating a metabolic syndrome
US20220227825A1 (en) Fgf21 variants
EP2152294B1 (fr) A bad bh3 domain peptides pour utilisation dans le traitement ou le retardement de l'apparition du diabète.
JP2008535797A (ja) ヒトレプチン由来のポリペプチドとその使用
WO2016172156A2 (fr) Mutants du facteur de croissance des fibroblastes (fgf) 1 et leurs procédés d'utilisation pour réduire le glucose sanguin
EP3491011A1 (fr) Protéines du facteur de croissance des fibroblastes (fgf) 1 ayant une capacité de réduction du glucose et une mitogénicité réduite
JP2018535964A (ja) 線維芽細胞増殖因子（ｆｇｆ）１アナログによるステロイド誘導性高血糖の処置
US20180050087A1 (en) Methods of treating lipodystrophy using fgf-1 compounds
WO2014089267A1 (fr) Protéines de fusion de la galactine-3
US20230097335A1 (en) Fibroblast growth factor 1 (fgf1) mutant proteins that selectively activate fgfr1b to reduce blood glucose
EP2391377A2 (fr) Peptides, compositions pharmaceutiques en contenant et leurs utilisations
US20220118052A1 (en) Materials and methods for modulating glucose uptake
KR20080021588A (ko) 메카노 성장 인자 펩티드 및 이들의 용도
KR20230034356A (ko) 활성이 감소된 glp-1r 효능제 펩티드
US7932227B1 (en) Lacritin-syndecan fusion proteins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14768989

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14768989

Country of ref document: EP

Kind code of ref document: A1